Trial reportPediatrics2024
Short Oral Antibiotic Therapy for Pediatric Febrile Urinary Tract Infections: A Randomized Trial.
Trial report in Pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Short- versus standard-course antibiotic therapy for urinary tract infection in children: a systematic review and meta-analysis.Pediatric nephrology (Berlin, Germany) · 2025Pooled it
- Short- versus standard-course antimicrobial therapy for children with urinary tract infection: A meta-analysis.Acta paediatrica (Oslo, Norway : 1992) · 2025Pooled it
- Circumcision and continuous antibiotic prophylaxis in preventing recurrent febrile urinary tract infection in boys with high-grade vesicoureteral reflux.Jornal de pediatria · 2026Article
- Urinary tract infections in children.Nature reviews. Urology · 2026Review
- Significant Publications on Infectious Diseases Pharmacotherapy in 2024.Journal of pharmacy practice · 2026Review
- Antibiotic Stewardship in Pediatric Urinary Tract Infections: Current Evidence and Practical Strategies.Antibiotics (Basel, Switzerland) · 2026Review
- Urinary tract infection in the neonatal intensive care unit.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- The Invisible Excess: Too Long Antibiotic Duration in the Pediatric Emergency Care.Antibiotics (Basel, Switzerland) · 2026Article
- Antibiotic-ResistantMicroorganisms · 2025Review
- Variability in Treatment of UTIs in Children With Genitourinary Anomalies in Children's Hospitals.Hospital pediatrics · 2025Article
- Shorter treatments for (febrile) urinary tract infections: are we there?Translational pediatrics · 2025Article
- Urinary Tract Infection in Children: An Up-To-Date Study.Biomedicines · 2024Review
- Insights into Hospitalized Children with Urinary Tract Infections: Epidemiology and Antimicrobial Resistance Patterns in Israel-A Single Center Study.Children (Basel, Switzerland) · 2024Article
- Outcomes associated with initial narrow-spectrum versus broad-spectrum antibiotics in children hospitalized with urinary tract infections.Journal of hospital medicine · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesFebrile urinary tract infection (fUTI) in well-appearing children is conventionally treated with a standard 10-day course of oral antibiotic. The objective of this study is to determine the noninferiority (5% threshold) of a 5-day amoxicillin-clavulanate course compared with a 10-day regimen to treat fUTIs.
methodsThis is a multicenter, investigator-initiated, parallel-group, randomized, controlled trial. We randomly assigned children aged 3 months to 5 years with a noncomplicated fUTI to receive amoxicillin-clavulanate 50 + 7.12 mg/kg/day orally in 3 divided doses for 5 or 10 days. The primary end point was the recurrence of a urinary tract infection within 30 days after the completion of therapy. Secondary end points were the difference in prevalence of clinical recovery, adverse drug-related events, and resistance to amoxicillin-clavulanic acid and/or to other antibiotics when a recurrent infection occurred.
resultsFrom May 2020 through September 2022, 175 children were assessed for eligibility and 142 underwent randomization. The recurrence rate within 30 days of the end of therapy was 2.8% (2/72) in the short group and 14.3% (10/70) in the standard group. The difference between the 2 groups was -11.51% (95% confidence interval, -20.54 to -2.47). The recurrence rate of fUTI within 30 days from the end of therapy was 1.4% (1/72) in the short group and 5.7% (4/70) in the standard group (95% confidence interval, -10.4 to 1.75).
conclusionsThis study demonstrates that a 5-day course is noninferior to a 10-day course of oral amoxicillin-clavulanate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.